UBAZF yields 18.10% · JNJ yields 2.13%● Live data
📍 UBAZF pulled ahead of the other in Year 1
Combined, UBAZF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UBAZF + JNJ for your $10,000?
Uzabase, Inc. provides information infrastructure to support decision-making in business activities primarily in Japan and internationally. It operates SPEEDA, a business information platform that provides insights for business strategy development and market analysis, including global corporate data, industry reports, market data, M&A deals, and expert insights to financial institutions and general businesses; FORCAS, a B2B marketing platform; and NewsPicks, a social business media that offers economic and business news articles. The company also operates INITIAL, a startup information platform that provides one-stop source to general data, financing, investors, and business partners of startups, as well as articles on related topics; and AlphaDrive, a consulting business that supports corporate clients in relation to new business development, next generation human resource development, and revitalising organizations. In addition, it operates MIMIR, a network business; SPEEDA EDGE, a market intelligent platform that offers industry-driven insights, including emerging tech trends, disruptors, partnership deals, and custom research; and UB VENTURES, a venture capital business that focuses on financing seed to early-stage SaaS and media startups. Uzabase, Inc. was incorporated in 2008 and is headquartered in Tokyo, Japan.
Full UBAZF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.